CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Down 90.3% in August

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 107,900 shares, a drop of 90.3% from the July 31st total of 1,110,000 shares. Based on an average trading volume of 5,160,000 shares, the days-to-cover ratio is presently 0.0 days.

CNS Pharmaceuticals Trading Down 7.1 %

Shares of NASDAQ:CNSP traded down $0.01 on Tuesday, reaching $0.17. The company had a trading volume of 2,003,368 shares, compared to its average volume of 2,073,815. CNS Pharmaceuticals has a 52-week low of $0.10 and a 52-week high of $137.50. The firm’s 50 day simple moving average is $0.97 and its 200-day simple moving average is $8.60. The firm has a market capitalization of $241,269.60, a PE ratio of 0.00 and a beta of 2.62.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CNS Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 122,000 shares of the company’s stock, valued at approximately $155,000. Armistice Capital LLC owned 1.96% of CNS Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.